# name
﻿Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives

# metadata.dc.description.abstract[].value
Neoadjuvant endocrine treatment (NET) associates to satisfactory rates of breast conservative surgery and conversions from inoperable to operable hormone receptor-positive (HR+)/HER2-negative breast cancer (BC), with less toxicities than neoadjuvant chemotherapy (NACT) and similar outcomes. Hence, it has been proposed as a logical alternative to NACT in patients with HR+/HER2- BC candidate to a neoadjuvant approach. Nevertheless, potential barriers to the widespread use of NET include the heterogeneous nature of patient response coupled with the long duration needed to achieve a clinical response. However, interest in NET has significantly increased in the last decade, owing to more in-depth investigation of several biomarkers for a more adequate patient selection and on-treatment benefit monitoring, such as PEPI score, Ki67 and genomic assays. This review is intended to describe the state-of-the-art regarding NET, its future perspectives and potential integration with molecular biomarkers for the optimal selection of patients, regimen and duration of (neo)adjuvant treatments.

# metadata.dc.relation.ispartof[].value
Critical Reviews in Oncology Hematology, 2023, vol. 181

# metadata.dc.source[].value
Articles publicats en revistes (Medicina)

# metadata.dc.title[].value
﻿Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives